Cognition Therapeutics Inc CGTX
Cognition Therapeutics Inc (Nasdaq: CGTX) is a CNS/neurology/psychiatry drug developer. Its lead program, zervimesine (CT1812), is in Phase 2 for early Alzheimer's disease; dementia with Lewy bodies. Its next catalyst on record is zervimesine: START Phase 2 topline results (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: zervimesine — START Phase 2 topline results (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| zervimesine (CT1812) START study (COG0203) | early Alzheimer's disease | small molecule | Phase 2 |
| zervimesine | dementia with Lewy bodies (DLB), psychosis; pivotal study planned | small molecule | Phase 2 |
Recent results and decisions
- Oct 22, 2026n/a Cognition Therapeutics announces FDA alignment on key elements of a pivotal Phase 3 trial of zervimesine in dementia with Lewy bodies.
With FDA's alignment on trial design, we are completing a protocol to support the planned registrational study in DLB, a disease with no approved treatments.
Filing - Jun 24, 2026positive Recent analysis of Phase 2 SHIMMER: zervimesine slowed progression of hallucinations and delusions by 89% vs placebo.
In a recent analysis of results from the Phase 2 study, zervimesine slowed progression of hallucinations and delusions by 89%.
Filing - Mar 26, 2026completed enrollment Enrollment completed (December 2025) in the 545-patient Phase 2 START trial; topline expected 2027.
Our 545-patient ‘START’ trial in early Alzheimer’s disease has completed enrollment.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.